Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis

Not Applicable

• Conditions: Hemochromatosis
• Interventions: Drug: Pantoprazole

• Registration Number: NCT01524757
• Lead Sponsor: Maastricht University Medical Center

Brief Summary

Hereditary Hemochromatosis (HH) is a genetic disorder of iron metabolism, resulting in excessive iron overload causing damage of different important organs like heart, liver, pancreas and joints. Complications and symptoms can regress by intensive treatment reducing the iron overload stores.Different genes have been identified playing a role in the pathophysiology of iron overload. A clinically important HFE gene mutation is the C282Y, located on chromosome 6. Phlebotomy is currently the standard therapy which consists of removal of 500 ml whole blood weekly, representing a loss of 250 mg iron. In naive patients between 20 to 100 phlebotomies are required to reduce the serum ferritine levels to 50 μg/L. Thereafter, a lifelong maintenance therapy of 3 to 6 phlebotomies yearly is needed.

For absorption, dietary iron ( 70%) is reduced by gastric acid form the ferric (Fe3+) to the ferrous form (Fe2+). Recently, in an observational open study, Hutchinson et al. found that HH patients treated with proton pump inhibitors (PPI) needed fewer phlebotomies, resulting in a drop of 2.5 (SEM 0.25) to 0.5 (SEM 0.25) liter per year.

Research question: The primary objective is to determine the effectiveness and cost effectiveness of PPI's compared to standard phlebotomy therapy in the prevention of iron overload in HH patients.

Multi-center trial in two hospitals in the South of Limburg (Atrium medical Center, Maastricht university medical center ) and hospital in Belgium (University Hospital Gasthuisberg). The study will be conducted in randomised double blind manner. The follow up will be one year.

Patients are randomized either for the group receiving a PPI or a placebo. Every 2 month the ferritin level is measured and decided if the patient need a phlebotomy (Ferritin \>100 µg/L).

Detailed Description

Not available

Study Timeline

• Status Verified: 2012-01
• Study First Submitted: 2012-01-31
• Study First Submitted QC: 2012-02-01
• Last Update Submitted: 2012-02-01
• Study First Posted: 2012-02-02
• Last Update Posted: 2012-02-02
• Study Start: 2012-03
• Primary Completion: 2013-08
• Study Completion: 2013-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

• Patients with hereditary hemochromatosis (HH), homozygous for C282Y, currently treated with phlebotomy as maintenance therapy for at least 12 months with ≥ 3 phlebotomies per year.
• Ferritin level between 50-100 μg/L at start of the inclusion.
• Age: 18 years- 60 years and weight > 50 kg.

Exclusion Criteria

• Patients receiving other therapies such as chelating therapy or forced dietary regimen.
• Patients younger than 18 years.
• HH patients with excessive overweight (BMI > 35).
• Patients who are mentally incapacitated.
• Women being pregnant or expecting/ planning to become pregnant during the one year period of the study.
• Patients with a malignancy.
• Patients already on PPI treatment.
• Patients who experienced side effects of PPI's.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
pantoprazol	Pantoprazole	-
placebo	Pantoprazole	-

Primary Outcome Measures

Name	Time	Method
the total number of phlebotomies for the group taking PPI treatment compared to the group taking placebo will be the primary endpoint of the study.	12 months

Secondary Outcome Measures

Name	Time	Method
number of participants with side effects	12 months

Trial Locations

Locations (3)

University hospital Gasthuisberg; 🇧🇪 Leuven, Limburg, Belgium

Atrium MC Parkstad; 🇳🇱 Heerlen, Limburg, Netherlands

Maastricht university medical center; 🇳🇱 Maastricht, Limburg, Netherlands